Corning Incorporated and SGD Pharma have inaugurated a pharmaceutical glass tubing facility in Telangana, India.

The facility will bring together Corning’s Velocity Vial technology and SGD Pharma’s vial-converting expertise, which will help address capacity challenges and quality requirements in primary glass packaging.

The plant will manufacture Type I borosilicate glass tubing, a material used for injectable drug packaging, direct injection delivery systems, diagnostics, and biologics.

By combining SGD Pharma’s vial-converting expertise with Corning’s Velocity Vial glass-coating technology, the collaboration will enhance vial quality, improve filling-line productivity, and accelerate the delivery of injectable treatments.

With tubing production and vial converting co-located, the facility will also deliver efficiencies in sustainability and product quality.

Chris Hudson, Vice President and General Manager, Corning Life Sciences, said: “This facility will play a vital role in India in accelerating the delivery of injectable treatments, supporting local pharmaceutical growth, and ensuring safer, more efficient access to critical medicines.”

Olivier Rousseau, CEO, SGD Pharma, said: “This joint venture with Corning marks a major milestone in our global growth strategy.

"By establishing a glass tubing facility in Telangana, we are not only securing a critical part of our supply chain but also bringing world-class technology to one of the fastest-growing pharmaceutical markets.

The new facility will also allow Corning to better serve customers in the region, ensuring faster lead times and strengthening supply chain resilience.

This localised manufacturing capacity will also help broaden the adoption of advanced glass tubing solutions for safer and more efficient delivery of critical medicines.

The joint venture between Corning and SGD Pharma was incorporated in April 2023, followed by a facility groundbreaking in June 2023.

Phase one for Velocity Vials production started in March 2024, followed by tubing production in late 2025.